Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients

Fundamental and Clinical Pharmacology

Volumn 23, Issue 5, 2009, Pages 625-631

  Felipe, Claudia R ^a   Park, Sung In ^a   Pinheiro Machado, Paula G ^a   Garcia, Riberto ^a   Casarini, Dulce E ^a   Moreira, Silvia ^a   Tedesco Silva Jr , Helio ^a   Medina Pestana, Jose O ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cyclosporine; Drug interaction; Kidney transplantation; Pharmacokinetics; Sirolimus

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CIRCADIAN RHYTHM; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MONITORING; DRUG POTENTIATION; EVENING DOSAGE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRIORITY JOURNAL;

ADULT; CIRCADIAN RHYTHM; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; SIROLIMUS;

EID: 69949168094     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00699.x     Document Type: Article

References (21)

1. Kahan B.D. Efficacy of SRL compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. Lancet (2000) 356 194 202.
2. Holt D.W. Therapeutic drug monitoring of immunosuppressive drugs in kidney transplantation. Curr. Opin. Nephrol. Hypertens. (2002) 11 657 663.
3. Zimmerman J., Harper D., Getsy J., Jusko W.J. Pharmacokinetic interaction between SRL and microemulsion CsA when orally administered jointly and 4 h apart in healthy volunteers. J. Clin. Pharmacol. (2003) 43 1168 1176.
4. Kaplan B., Meier- Kriesche H.U., Napoli K.L., Kahan B.D. The effects of relative timing of SRL and CsA microemulsion formulation coadministration on the pharmacokinetic of each agent. Clin. Pharmacol. Ther. (1998) 63 48 53.
5. Stepkowski S.M., Napoli K.L., Wang M.E., Qu X., Chou T.C., Kahan B.D. Effects of the pharmacokinetic interaction between orally administered SRL and CsA on the synergistic prolongation of heart allograft survival in rats. Transplantation (1996) 62 986 994.
6. Podder H., Stepkowski S.M., Napoli K.L. et al. Pharmacokinetic interaction augment toxicities of SRL/ CsA combination. J. Am. Soc. Nephrol. (2001) 12 1059 1071.
7. Oberbauer R., Segoloni G., Campistol J.M. et al. Early CsA withdrawal from a SRL-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant. Int. (2005) 18 22 28.
8. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J. Pharm. Pharmacol. (1999) 51 887 890.
9. Di Marco G.S., de Andrade M.C., Felipe C.R. et al. Determination of sirolimus blood concentration using high- performance liquid chromatography with ultraviolet detection. Ther. Drug Monit. (2003) 25 558 564.
10. Zimmerman J.J. Exposure-response relationship and drug interactions of sirolimus. AAPS J. (2004) 6 28.
11. Ohlman S., Lindholm A., Hagglund H., Sawe J., Kahan B.D. On the intraindividual variability and chronobiology of cyclosporine pharmacokinetics in renal transplantation. Eur. J. Clin. Pharmacol. (1993) 44 265 269.
12. Vincenti F., Mendez R., Curtis J. et al. A multicenter, prospective study of C2- monitored CsA microemulsion in a US population of de novo renal transplant recipients. Transplantation (2005) 80 910 916.
13. Lissoni P., Rovelli F., Brivio F., Brivio O., Fumagalli L. Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/ dark rhythm of the pineal hormone melatonin in healthy humans. Nat. Immunol. (1998) 16 1 5.
14. Christians U., Schmitz V., Haschke M. Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert. Opin. Drug. Metab. Toxicol. (2005) 1 1 14.
15. Wong S., Wong H.T., Wacher V.J. Minimal effect of ketoconazole on CsA (SandCyA) oral absorption and firt- pass metabolism in ratis: evidence of a significant vehicle effect on SangCyA absorption. Biopharm. Drug Dispos. (2002) 23 53 57.
16. Hesselink D.A., van Gelder T., van Schaik R.H. The pharmacogenetics of calcineurin inhibitors: one step closer toward individualized immunosuppression? Pharmacogenomics (2005) 6 323 337.
17. Yates C.R., Zhang W., Song P. et al. The effect of CYP3A45 and MDR1 polymorphic expression on CsA oral disposition in renal transplant patients. J. Clin. Pharmacol. (2003) 43 555 564.
18. Sattler M., Guengerich F.P., Yun C.H., Christians U., Sewing K.F. Cytochrome P-450 3A enzymes are responsible for biotransformation oh FK506 and rapamycin in man and rat. Drug. Met. Dis. (1992) 20 753 761.
19. Kronbach T., Fischer V., Meyer U.A. CsA metabolism in human liver: identification of a cytochrome P-450III gene family as the major CsA-metabolizing enzyme explains interactions of CsA with other drugs. Clin. Pharmacol. Ther. (1988) 43 630 635.
20. Mourad M., Mourad G., Wallemacq P. et al. SRL and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. Transplantation (2005) 80 977 984.
21. Lemahieu W.P., Maes B.D., Verbeke K., Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporine vs. tacrolimus vs SRL. Am. J. Transplant. (2004) 4 1514 1522.